[Biology of haemostasis disorders: photometric platelet aggregation test]
Haute Autorité de Santé
Record ID 32016000268
French
Authors' objectives:
The National Salaried Workers' Health Insurance Fund (CNAMTS) asked HAS to assess the value of the different laboratory tests for haemostasis abnormalities with a view to updating the section in the Nomenclature of Procedures in Laboratory Medicine (NABM) containing the procedures in laboratory medicine for measuring abnormalities of haemostasis (subsection 5-02). One of those tests is the photometric platelet aggregation test (PAT), which is not an NABM procedure. The PAT is regarded as the reference test for the
assessment of platelet function, for which it is still the most used test. This technique measures aggregation in platelet-rich plasma (PRP) obtained after low-speed centrifugation of a sample of the patient's blood collected in sodium citrate. Aggregation is measured by a photometric technique after the addition of various inducers, also called aggregating agents or agonists. Since the preanalytical and analytical requirements are relatively demanding (for example blood sampling conditions, storage of the sample, time for carrying out the
examination, preparation of platelet-rich and platelet-poor plasmas, centrifugation conditions, etc.), the photometric platelet aggregation test would need to be carried out at experienced centres that are sufficiently busy to maintain expertise in using the technique and interpreting the results.
Authors' recommendations:
According to the different documents analysed, the photometric platelet aggregation test is recommended:
- for the diagnosis of haemorrhagic disorders;
- for the diagnosis of heparin-induced thrombocytopenia (HIT), combined with an immunological test, in the following cases:
– a relative drop in platelets, in two successive counts, of 30 % to 50 %, during treatment with heparin and/or a platelet count of < 100 to 150 G/L in the absence of any earlier count;
- venous or arterial thrombosis during treatment with heparin;
- thrombosis or thrombocytopenia, even if the patient has been off heparin for a few days;
- resistance to heparin therapy with spread of the thrombotic process.
On the other hand, on the basis of the different documents analysed, testing for resistance to antiplatelet drugs, whatever the method used, and thus including the photometric platelet aggregation test, is at present not recommended for routine individual use.
Details
Project Status:
Completed
URL for project:
http://www.has-sante.fr/portail/jcms/c_1009982/en/biology-of-haemostasis-disorders?xtmc=&xtcr=42
Year Published:
2011
URL for published report:
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-08/biologie_anomalie_hemostase_t3_tap_-_rapport_devaluation_2011-08-10_14-55-5_343.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
France
MeSH Terms
- Humans
- Blood Coagulation Disorders
- Blood Coagulation Tests
- Photometry
- Platelet Aggregation
- Platelet Function Tests
Contact
Organisation Name:
Haute Autorité de Santé
Contact Address:
2 avenue du Stade de France, 93218 Saint-Denis La Plaine Cedex, France. Tel: +33 01 55 93 71 88; Fax: +33 01 55 93 74 35;
Contact Name:
has.seap.secretariat@has-sante.fr
Contact Email:
has.seap.secretariat@has-sante.fr
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.